Zeng Siping, Guan Gangyun, Qin Qiuwei, Xie Huadong, Meng Yongyan, Zhao Qiyue
Department of Urology, Liuzhou Workers' Hospital, Liuzhou 545007, Guangxi Zhuang Autonomous Region, China.
Department of Obstetrics and Gynecology, Xiangzhou People's Hospital, Laibin 545800, Guangxi Zhuang Autonomous Region, China.
Evid Based Complement Alternat Med. 2021 Nov 9;2021:2237069. doi: 10.1155/2021/2237069. eCollection 2021.
To analyze the efficacy of androgen deprivation therapy (ADT) combined with radiation therapy (also known as radiotherapy) for prostate cancer.
The clinical data of 94 prostate cancer patients treated in the Oncology Department of Xiangzhou People's Hospital from January 2017 to January 2018 were retrospectively analyzed, and the patients were divided into the combined group and the reference group according to their admission order, with 47 cases each. The patients in the reference group only received the radiotherapy, and on this basis, those in the combined group accepted ADT, so as to evaluate the efficacy of different treatment methods by comparing the patients' serum total prostate-specific antigen (T-PSA), vascular endothelial growth factor (VEGF), and other indicators and analyze the relevant factors affecting patients' prognosis by Cox single-factor and multi-factor regression models.
Compared with the reference group after treatment, the patients in the combined group obtained significantly lower T-PSA and VEGF levels ( < 0.001), significantly higher objective remission rate and disease control rate ( < 0.05), and remarkably longer modified progression-free survival (mPFS) and overall survival (OS) ( < 0.001), and after the multi-factor research, it was found that the Gleason score of 8-10, positive lymphatic metastasis, and single radiotherapy were the factors affecting the clinical prognosis of prostate cancer.
Combining ADT with radiotherapy ensures a better survival benefit for prostate cancer patients and has a fairly well efficacy. Further study will be conducive to establishing a better solution for such patients.
分析雄激素剥夺疗法（ADT）联合放射治疗（也称为放疗）用于前列腺癌的疗效。
回顾性分析2017年1月至2018年1月在香洲区人民医院肿瘤科接受治疗的94例前列腺癌患者的临床资料，根据入院顺序将患者分为联合组和参照组，每组47例。参照组患者仅接受放疗，联合组在此基础上接受ADT，通过比较患者血清总前列腺特异性抗原（T-PSA）、血管内皮生长因子（VEGF）等指标评估不同治疗方法的疗效，并通过Cox单因素和多因素回归模型分析影响患者预后的相关因素。
与治疗后的参照组相比，联合组患者的T-PSA和VEGF水平显著降低（<0.001），客观缓解率和疾病控制率显著升高（<0.05），改良无进展生存期（mPFS）和总生存期（OS）显著延长（<0.001），多因素研究后发现，Gleason评分为8-10、淋巴结转移阳性和单纯放疗是影响前列腺癌临床预后的因素。
ADT与放疗联合可确保前列腺癌患者获得更好的生存获益，且疗效相当不错。进一步研究将有助于为这类患者建立更好的治疗方案。
